BioProtect Ltd. is a technology platform company that designs, develops, and manufactures innovative bioabsorbable spacers. The technology may suit various clinical applications, including spacing between healthy and treated tissue for radiation oncology and general surgery.
Our vision is to become a world leader in spacing technology to protect healthy organs during radiation therapy treatment.
BioProtect’s first commercially available application in Europe is the BioProtect Balloon Implant™ System. The spacer aims to protect healthy tissue in patients receiving radiotherapy for prostate cancer. The BioProtect Balloon spacer aims to reduce undesirable side effects and treatment costs and improve the patients’ quality of life. The Company is undergoing the FDA regulatory clearance process and preparing for associated commercial scale-up.
BioProtect is ISO 13485:2016 certified and holds a CE Mark for its BioProtect Balloon.
Dr. Dekel has over 17 years of experience in the medical device industry. He co-founded OrthoSpace (acquired by Stryker in 2019) and Orthospin. Currently, Dr. Dekel has a leading role in various early-stage companies.
Michal has 25 years of executive management experience in MedTech and digital health startups in Israel and the US, including ByPass, AST (acquired by Boston Scientific), GI View, TriReme Medical (IPO), and others. Michal is involved in all Triventures investments and serves as an active board member in most Triventures’ portfolio companies.
Merav has vast experience in mobilizing companies from small startups to the IPO stage and beyond. Merav serves as a director in several Med-tech companies.
Eyal serves on the boards of many of Peregrine’s portfolio companies. Before founding Peregrine Ventures, Eyal co-founded and led the business development efforts of several medical technology companies, including PharmaSys (acquired by Elan Corp.) ECR (acquired by AVX Corp.), Visioncare Ophthalmic Technologies, and BioControl Ltd.
Deputy General Manager of KB Investment – Previously, Min led product management and business development in BC World Pharm (Kosdaq listed) to launch multiple pharmaceutical products and enter multiple cross-border collaborations. Before joining KB Investment, Min led biotech investment at Mega Investment, and now is expanding the portfolio global portfolio at KB Investment, including BiomX, Adicet, Arvelle, Senti, and more.
Ph.D. Economics, MA International Relationships with 12 years of business experience. Gennadiy serves as the Chairman and CEO of UCG, Russia’s leading chemical, polymer, resin, and engineering plastics distributor. Gennadiy has successful experience as a founder and BOD director in telecom, engineering, and construction companies.